COMP <GO>
MDT vs JNJ // REVENUE GROWTH (YOY)
Medtronic plc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MDT 7
— JNJ 8
▲ REVENUE GROWTH (YOY) LEADER: MDT
LAST: $96.54 (-0.59%) • MKT CAP: $124.22B
revenue-growth
8.40%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.00% | 67.90% | -2.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 25.50% | -17.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.4x | 18.5x | -1.10 | MDT | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 2.97% | +1.40 | MDT | /fcf-yield <GO> |
| Operating Margin | 17.80% | 34.70% | -16.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 8.40% | 6.00% | +2.40 | MDT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.93% | 0.00% | +2.93 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.08 | 5.59 | -2.51 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | MDT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.20% | -0.60 | MDT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.5 | 60.4 | +0.19 | MDT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.08 | -0.17 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 23.0x | +117.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $124.22B | $662.49B | -$538.27B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDT REV | JNJ REV | MDT GROSS % | JNJ GROSS % | MDT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.36B | $94.19B | 65.0% | 67.9% | $5.43B | $19.70B |
| FY 2024 | $33.54B | $88.82B | 65.3% | 69.1% | $5.18B | $19.84B |
| FY 2023 | $32.36B | $85.16B | 44.0% | 44.0% | $5.33B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDT // BETA 0.91
JNJ // BETA 1.08